IDO1 levels were associated with aggressive clinico-pathologic features of the tumor such as extrathyroidal extension and multifocality, suggesting that disruption of antitumor immunity by IDO1 expression, and thus, infiltration of FoxP3+ Treg cells may contribute to tumor progression in PTMC. The gene discussed is IDO1; the disease is neoplasm.